BI 1356 BS in Japanese Patients With Type 2 Diabetes Mellitus

Phase 2 Completed 72 enrolled Boehringer Ingelheim

RandomizedParallel-groupDouble-blindTreatment

Summary

Study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 1356 BS (0.5 mg, 2.5 mg, and 10 mg) administered orally once daily for 28 days in Japanese patients with type 2 diabetes mellitus.

Timeline

Start: 2007-02
Primary completion: 2007-06
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Linagliptin	Unknown	0.5 mg	Oral
Subject	Linagliptin	Unknown	2.5 mg	Oral
Subject	Linagliptin	Unknown	10 mg	Oral

BI 1356 BS in Japanese Patients With Type 2 Diabetes Mellitus

Summary

Timeline

Drugs

Indications